Highest-materiality recent filing
DSS enters $2.45M convertible note and warrant deal with related party Alset International
Loan of $2,450,000 via convertible promissory note at 3% simple interest.
DSS prices and closes $1.0M underwritten public offering; net proceeds ~$0.7M
Offering of 900,000 shares of common stock at $1.00/share for gross proceeds of $1.0M; closed Feb 5, 2026.
DSS shareholders elect directors, ratify auditor, approve say-on-pay at 2025 meeting
All seven director nominees elected: Ambrose Chan Heng Fai, José Escudero, Lim Sheng Hon Danny, Wai Leung William Wu, Tung Moe Chan, Hiu Pan Joanne Wong, Shui Yeung Frankie Wong.
DSS converts $12M Impact Biomedical debt into 31.9M shares of Impact common stock
DSS settled all outstanding debt owed by Impact Biomedical under a $12M original note and amendments.
DSS replaces auditor Grassi & Co. with HTL International; no disagreements reported
Dismissed Grassi & Co., CPAs, P.C. as independent auditor on June 27, 2025.
DSS grants 1M shares to director's affiliated company as bonus compensation
Board approved issuance of 1,000,000 shares of common stock to Heng Fai Holdings Limited, owned by Director Heng Fai Ambrose Chan, as a bonus for services rendered.
DSS subsidiary invests $1M in True Partner Capital; DSS sells $200K of own stock
Subsidiary True Partner International invested HK$7.8M (~$1M) for 19.5M shares in True Partner Capital Holding at HK$0.40/share.
DSS, Inc. raises ~$1M via private placement of 1,025,746 shares at $0.9749/share
Sold 820,597 shares to Alset Inc. and 205,149 shares to Heng Fai Ambrose Chan at $0.9749 per share.
DSS stockholders elect all seven director nominees and ratify auditor at 2024 annual meeting
All seven director nominees elected; broker non-votes of 1,079,704 on each.
DSS restates 2023 10-K; $23.5M overstatement of deconsolidation loss, discontinued ops omitted
Audit Committee determined 2023 10-K financials unreliable due to errors; restated via 10-K/A filed Oct 22, 2024.
DSS CEO Frank Heuszel steps down; COO Jason Grady named Interim CEO effective Aug 23, 2024
CEO Frank Heuszel resigns effective Aug 23, 2024; remains on American Medical REIT board.
CEO Frank Heuszel to step down; Jason Grady appointed interim CEO
Frank Heuszel resigns as CEO effective Aug 23, 2024; no disagreement with company on operations, policies, or practices.
Mr. Frank D. Heuszel, announced that effective on the close of business on August 23, 2024, he will step down as the Chief Executive Officer
Effective August 23, 2024, the Board of Directors of DSS, Inc. elected Mr. Jason Grady as the Company’s new Interim Chief Executive Officer.
Effective August 23, 2024, the Board of Directors of DSS, Inc. elected Mr. Jason Grady as the Company’s new Interim Chief Executive Officer.
Mr. Frank D. Heuszel, announced that effective on the close of business on August 23, 2024, he will step down as the Chief Executive Officer of DSS.
Max materiality 0.85 · Median 0.50 · Most common event other_material